The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, BioXcel Therapeutics Inc (NASDAQ: BTAI) closed at $1.6 up 4.58% from its previous closing price of $1.53. In other words, the price has increased by $4.58 from its previous closing price. On the day, 0.53 million shares were traded. BTAI stock price reached its highest trading level at $1.6 during the session, while it also had its lowest trading level at $1.5259.
Ratios:
For a deeper understanding of BioXcel Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.17.
Upgrades & Downgrades
In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 34991188 and an Enterprise Value of 108101184. For the stock, the TTM Price-to-Sale (P/S) ratio is 46.65. Its current Enterprise Value per Revenue stands at 143.752 whereas that against EBITDA is -2.156.
Stock Price History:
The Beta on a monthly basis for BTAI is 0.20, which has changed by -0.7584541 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, BTAI has reached a high of $9.26, while it has fallen to a 52-week low of $1.17. The 50-Day Moving Average of the stock is -16.91%, while the 200-Day Moving Average is calculated to be -30.26%.
Shares Statistics:
For the past three months, BTAI has traded an average of 734.91K shares per day and 468080 over the past ten days. A total of 21.87M shares are outstanding, with a floating share count of 21.02M. Insiders hold about 3.89% of the company’s shares, while institutions hold 10.78% stake in the company. Shares short for BTAI as of 1765756800 were 979751 with a Short Ratio of 1.33, compared to 1763078400 on 1580569. Therefore, it implies a Short% of Shares Outstanding of 979751 and a Short% of Float of 4.6.
Earnings Estimates
Currently, 2.0 analysts are dedicated to thoroughly evaluating and rating the performance of BioXcel Therapeutics Inc (BTAI) in the stock market.The consensus estimate for the next quarter is -$0.72, with high estimates of -$0.59 and low estimates of -$0.83.
Analysts are recommending an EPS of between -$6.2 and -$7.53 for the fiscal current year, implying an average EPS of -$6.78. EPS for the following year is -$3.05, with 4.0 analysts recommending between -$2.07 and -$4.24.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $166.67k this quarter.It ranges from a high estimate of $200k to a low estimate of $100k. As of. The current estimate, BioXcel Therapeutics Inc’s year-ago sales were $366kFor the next quarter, 3 analysts are estimating revenue of $366.67k. There is a high estimate of $700k for the next quarter, whereas the lowest estimate is $100k.
A total of 3 analysts have provided revenue estimates for BTAI’s current fiscal year. The highest revenue estimate was $600k, while the lowest revenue estimate was $500k, resulting in an average revenue estimate of $554.03k. In the same quarter a year ago, actual revenue was $2.27MBased on 4 analysts’ estimates, the company’s revenue will be $2.86M in the next fiscal year. The high estimate is $6.08M and the low estimate is $400k.
